Fertility
Béa Fertility hires Elvie’s Darren Goode as a key commercial advisor
Béa aims to offer access to fertility care to thousands of couples struggling to conceive
Elvie’s former president and global chief marketing officer is taking up a new role as a leading advisor at femtech start-up Béa Fertility.
Darren Goode led Elvie to become a health tech brand with revenues exceeding US$26m. He now joins Béa as the team gears up to bring its fertility device to market.
Béa Fertility is developing the world’s first clinical-grade at-home fertility treatment by bringing back intracervical insemination (ICI) in an attempt to level the playing field when it comes to assisted conception and provide access to affordable fertility treatment
Co-founded by Tess Cosad, medical doctor Dr Louise Rix and product engineer George Thomas, the company aims to become the first affordable step on the fertility journey for people struggling to conceive.
Expected to launch in summer 2023, the Béa device will enable couples with infertility to carry out a simple ICI treatment at home, before exploring other costly clinical treatment options.
ICI has been shown to have efficacy of 50 per cent over six cycles of treatment, and was recently included in the NICE clinical guidelines as a recommended approach to fertility treatment.

Daren Goode joins Béa Fertility ahead of product launch
The start-up raised US$1m in pre-seed funding last year to expand their team and bring their fertility solution to market.
As a key advisor, Goode will help steer Béa’s marketing and growth strategies, with the aim of making the Béa device a category leader.
He will support the creation of a commercial infrastructure to support both UK and international growth, working with the CEO on brand strategy, positioning, growth and fundraising.
Darren brings over twenty-five years’ global marketing and commercial experience from the likes of Apple, L’Oreal, P&G, Paramount Pictures, Elvie and Babylon Health.
“I’m really excited to be joining Tess and the wider Béa team at this critical stage in their journey,” the new adviser said.
“My first child was born through IVF, so I’m acutely aware of the complex challenges surrounding fertility. Currently, there’s really nothing available between trying (and struggling) to conceive and going to a fertility clinic.
“This is what drew me to Béa. This is the first time I’ve seen fertility innovation that isn’t just offering advice or a new route into clinics, but is getting to the very heart of the problem and offering a totally new treatment solution.”
He added: “My role will be equal parts operational, practical, philosophical and pastoral. Tess is an inspiring founder and I can’t wait to see where we can take this.”
Tess Cosad, CEO and co-founder at Béa Fertility, said: “I’ve been working with Darren since the inception of Béa, and at every step of the journey his advice has been invaluable.
“I couldn’t think of a better leader and advocate to have in our corner, and look forward to seeing where we can take the company with Darren on board.”
Insight
Covid vaccine not linked to decrease in childbirth, study finds
Insight
Parents sue IVF clinic after delivering someone else’s baby
A Florida couple have sued an IVF clinic after giving birth to a baby who is not genetically related to either of them.
Tiffany Score and Steven Mills hired IVF Life, which operates as the Fertility Center of Orlando in Longwood to help them conceive about five years ago using in vitro fertilisation.
The couple had an embryo implanted in April and welcomed a baby girl nine months later, but soon suspected the clinic had made an error.
Both Score and Mills are white, but the baby had the appearance of a racially non-Caucasian child, according to the lawsuit.
Genetic testing confirmed that the baby is not biologically theirs. The couple filed the lawsuit on 22 January after allegedly trying to contact the clinic multiple times without getting a response.
Jack Scarola, one of the couple’s lawyers, told the Orlando Sentinel: “They have fallen in love with this child. They would be thrilled in the knowledge that they could raise this child.
“But their concern is that this is someone else’s child, and someone could show up at any time and claim the baby and take that baby away from them.”
Score and Mills are also concerned that one of the three fertilised eggs they had frozen at the clinic may have been mistakenly implanted into someone else.
They have demanded that the clinic share what happened with all other patients who had embryos stored at the facility during the year before Score gave birth. They also want IVF Life to pay for genetic testing of every child born as a result of its services over the last five years, and to account for their remaining embryos.
The couple said in a statement: “We love our little girl. We would hope to be able to continue to raise her ourselves with confidence that she won’t be taken away from us.
“At the same time, we are aware that we have a moral obligation to find and notify her biological parents, as it is in her best interest that her genetic parents are provided the option to raise her as their own.”
A family spokesperson said: “Based upon leads discovered to date, and despite the lack of help or cooperation from the clinic, there is hope that we will be able to introduce our daughter to her genetic parents and to find our own genetic child soon.”
The lawsuit names IVF Life LLC and Dr Milton McNichol, who runs the clinic.
The Fertility Center of Orlando had posted a notice on its website stating it is “actively cooperating with an investigation to support one of our patients in determining the source of an error that resulted in the birth of a child who is not genetically related to them.”
The notice was removed after a court hearing on Wednesday.
During the hearing, the judge ordered the clinic to submit a thorough plan for handling the situation by Friday.
McNichol was reprimanded by Florida’s Board of Medicine in May 2024 after an inspection of the clinic in June 2023 revealed several issues, including equipment that did not meet current performance standards, failure to comply with a risk-management plan and missing medication.
He was fined US$5,000.
Fertility
Femtech World Awards to celebrate breakthrough fertility innovations
Fertility innovation is to set to take centre stage at Femtech World’s third annual awards event.
The Femtech World Awards will celebrate some of the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.
The Fertility Innovation of the Year award celebrates a pioneering product, service or initiative that is transforming fertility care and support.
The winner will have demonstrated exceptional innovation in helping individuals or couples navigate fertility journeys, whether through technology, treatments, education, accessibility, or emotional support.
Consideration will be given to scientific advancement, inclusivity, user impact and the ability to break barriers in fertility health.
The award is sponsored by FinDBest IVF – a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
Launched in 2024, the platform addresses a long-standing challenge in the MedTech sector—fragmented, costly, and inefficient market access—by offering a curated, country-specific directory of active partners, complete with key segmentation, certification indicators, and direct contact tools.
From consumables and lab equipment to AI-powered embryo selection and genetic testing solutions, FinDBest makes it faster and easier for companies to scale internationally—without relying on expensive congresses or cold outreach.
Juan A. Jiménez is founder and CEO of FinDBest IVF.
He said: “As part of its commitment to driving smarter access to reproductive innovation, FinDBest IVF is proudly supporting the Femtech World Fertility Innovation Awards for the second year in a row.
“This collaboration reflects two core beliefs at the heart of the platform.
“First, FinDBest IVF was created to accelerate not only the discovery of innovative fertility solutions but their global adoption.
“By supporting these awards, the platform helps amplify breakthrough technologies—from AI-based egg quality tools to next-gen IVF microdevices—and ensures they can reach the right partners and clinics faster.
“Second, the Awards align with FinDBest’s vision of building a 360-degree commercialisation ecosystem, where innovation is not just recognised, but connected to real-world opportunities.
“Many award nominees are pioneering startups and clinical researchers—exactly the kind of innovators who benefit from FinDBest’s support in navigating regulatory complexity, distributor validation, and go-to-market strategies across diverse regions.
“Together with Femtech World, FinDBest IVF is helping to spotlight, support, and scale the future of fertility care.”
Find out more about the Femtech World Awards and enter for free here.
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight2 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026






1 Comment